Last reviewed · How we verify

NCT00549744

Clinical Endpoint Trial Investigating Once Daily and Bronchodilator Dosing

Completed Phase 2 Last updated 26 June 2017
What this trial tests

Phase 2 trial testing GSK256066 in Asthma in 78 participants. Completed in 27 August 2008.

Timeline
16 November 2007
Primary endpoint
27 August 2008
27 August 2008

Quick facts

Lead sponsorGlaxoSmithKline
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Primary purposetreatment
Enrollment78
Start date16 November 2007
Primary completion27 August 2008
Estimated completion27 August 2008
Sites3 locations across New Zealand, South Africa

Drugs / interventions tested

Conditions studied

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 18 to 65, female only, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Subjects will attend the unit for out-patient visits on Day 1, Day 7, Day 14 and Day 15 of each treatment period. The washout period between each treatment period will be a minimum of 10 days and maximum of 28 days. Subjects will participate in 3 treatment periods.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022.
    Crocetti L, Floresta G, Cilibrizzi A, Giovannoni MP. · · 2022 · cited 85× · PMID 35956914 · DOI 10.3390/molecules27154964

Verify or expand the search:

Other trials of GSK256066

Trials testing the same drug.

Other recruiting trials for Asthma

Currently open trials in the same condition.

Other GlaxoSmithKline trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00549744.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing